Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macrophage activation syndrome.

Angelo Ravelli1

  • 1Pediatria II, Istituto G. Gaslini, Università di Genova, Italy. angeloravelli@ospedale-gaslini.ge.it

Current Opinion in Rheumatology
|August 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same author

Enhancing the precision of clinical assessment in juvenile idiopathic arthritis through the JADAS.

Pediatric rheumatology online journal·2026
Same author

A novel approach to the clinical assessment of juvenile fibromyalgia syndrome: the Juvenile Fibromyalgia Multidimensional Assessment Report.

Clinical and experimental rheumatology·2026
Same author

Systematic Literature Review Informing Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-Endorsed Recommendations for the Treat-to-Target Strategy in Juvenile Dermatomyositis.

The Journal of rheumatology·2026
Same author

Introducing a parent-centred composite disease activity score for remote monitoring in juvenile dermatomyositis.

Rheumatology (Oxford, England)·2026
Same author

Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study.

The Lancet. Rheumatology·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Macrophage activation syndrome (MAS) is a severe inflammatory disorder in children. Early diagnosis is challenging, but serum ferritin levels may aid in identifying MAS and monitoring treatment effectiveness.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Hematology

Background:

  • Macrophage activation syndrome (MAS) is a life-threatening complication of childhood systemic inflammatory disorders.
  • It involves excessive T lymphocyte and macrophage activation, potentially linked to defective perforin function, similar to hemophagocytic lymphohistiocytosis.

Purpose of the Study:

  • To review the diagnostic challenges and therapeutic strategies for Macrophage Activation Syndrome (MAS).
  • To highlight the role of serum ferritin in MAS diagnosis and management.

Main Methods:

  • Literature review of Macrophage Activation Syndrome (MAS) and related conditions.
  • Analysis of diagnostic markers and therapeutic interventions, including novel agents.

Main Results:

Related Experiment Videos

  • Early diagnosis of MAS remains difficult despite well-documented clinical features.
  • Serum ferritin levels are a valuable indicator for MAS diagnosis, disease activity, treatment response, and prognosis.
  • Cyclosporin A shows efficacy in corticosteroid-resistant MAS.
  • Etanercept is suggested as a potential adjunctive therapy.

Conclusions:

  • MAS is increasingly recognized as a secondary hemophagocytic syndrome, prompting reclassification.
  • Serum ferritin measurement is crucial for effective MAS management.
  • Current and emerging therapies offer hope for managing this severe pediatric condition.